

**Kentucky Department of Insurance
Financial Impact Statement
Health Benefit Mandate Statement
HB 180 GA/BR 229**

- I. Mandating health insurance coverage of BR 229/HB 180, is not expected to materially increase premiums, based upon our analysis of the proposed mandate and our experience with similar health insurance benefits. The proposed mandate requires that health benefit plans provide coverage for biomarker testing when ordered by a qualified health care provider for the purpose of diagnosis, treatment, appropriate management, or ongoing monitoring of an insured's disease or condition when the test is supported by medical and scientific evidence. The level of costsharing is not mandated. Additionally, the proposed mandate specifies that it should not be construed to require the coverage of biomarker testing for screening purposes. Our analysis includes health benefit plans, for all fully insured policies in Kentucky, excluding Medicaid and state employees.

The proposed BR 229/HB 180, as described above, is not expected to materially increase the total cost of health care in the Commonwealth, based upon our analysis of the proposed mandate and our experience with similar health insurance benefits. Our analysis includes health benefit plans, for all fully insured policies in Kentucky, excluding Medicaid and state employees.

The proposed BR 229/HB 180, as described above, is not expected to materially increase administrative expenses of insurers, based upon our analysis of the proposed mandate and our experience with similar health insurance benefits. The proposed legislation for all insured health benefit plan coverages, excluding Medicaid and state employees, is not expected to materially increase administrative expenses of Insurers. It is our assumption that Insurers will have this information readily available, and the additional administrative requirements imposed by this mandate would not significantly impact the administrative costs relative to current levels.

Our analysis included the use of data and statistics from, a California Fiscal Impact Statements for SB 912 and SB 535, actuarial judgement, and a 2021 Annual Data Report provided by DOI.


Note: It is our understanding and assumption that a significant portion of medically necessary biomarker tests are already covered by health benefit plans.

Disclosure: L&E made several assumptions in performing the analysis. Several of these assumptions are subject to material uncertainty and it is not unexpected that actual results could materially differ from these estimates if a more in-depth analysis were to be performed.

Disclosure: Due to the material disclosure requirements required therein, we must acknowledge that the content of this report may not comply with Actuarial Standard of Practice No. 41 Actuarial Communications.



Traci Hughes, F.S.A. M.A.A.A.



Brian Stentz, A.S.A. M.A.A.A.

LEWIS & ELLIS, INC.
February 15, 2023

LEWIS & ELLIS, INC.
February 15, 2023

Sharon P. Clark

2/16/23

(Signature of Commissioner/Date)

FIS Actuarial Form 6-03